Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 5/20 | 0.39 |
| ▸ | NPC1 | O15118 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.37 |
| ▸ | RAF1 | P04049 | 1/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | SCN4A | P35499 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1384144 | 0.89 | SCN4A (0.53) | MEN1KMT2AALDH1A1SCN4AMAPT | |
| SCHEMBL20054187 | 0.86 | AKT1 (0.30) | — | |
| SCHEMBL25081050 | 0.82 | MAOB (0.51) | RAB9ANPC1CA12MAOBCASP3 | |
| Butylamine SCHEMBL8653267 | 0.82 | TLR8 (0.44) | MEN1KMT2AALDH1A1MAPK13MAPK12 | |
| SCHEMBL4063789 | 0.78 | AKT1 (0.43) | SMN1; SMN2POLBRAB9ANPC1MEN1 | |
| SCHEMBL13514507 | 0.78 | METAP2 (0.44) | — | |
| SCHEMBL856079 | 0.78 | METAP2 (0.44) | MAPK1SMN1; SMN2RAB9ANPC1MEN1 | |
| SCHEMBL5478060 | 0.78 | METAP2 (0.44) | MAPK1SMN1; SMN2POLBRAB9ANPC1 | |
| SCHEMBL4379353 | 0.78 | IDO1 (0.39) | — | |
| SCHEMBL1283665 | 0.78 | KEAP1 (0.44) | SMN1; SMN2RAB9ANPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025132825-A1 | 1H-IMIDAZO[4,5-C]QUINOLINE METAL-BASED COMPLEXES USEFUL AS MEDICAMENTS | FUNDACIÓN DONOSTIA INTERNATIONAL PHYSICS CENTER - DIPC (ES) | 2025-06-26 | — | — | WO | claimed |
| EP-3500562-B1 | SUBSTITUTED AZOLE DERIVATIVES FOR GENERATION, PROLIFERATION AND DIFFERENTIATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS | NAT UNIV SINGAPORE (SG) | 2023-11-15 | — | — | EP | claimed |
| US-20140031289-A1 | POLY(ORGANOPHOSPHAZENE) CONTAINING DEGRADATION CONTROLLABLE IONIC GROUP, PREPARATION METHOD THEREOF AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2014-01-30 | — | — | US | claimed |
| US-20110136796-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-06-09 | — | — | US | claimed |
| EP-4323354-B1 | 2-((4-((S)-2-(4-CHLORO-2-FLUOROPHENYL)-2-METHYLBENZO[D][1,3]DIOXOL-4-YL)PIPERIDIN-1-YL)METHYL)-1-(((S)-OXETAN-2-YL)METHYL)-1H-IMIDAZOLE DERIVATIVES AS ACTIVATORS OF THE GLP1 RECEPTOR FOR THE TREATMENT OF OBESITY | NOVARTIS AG (CH) | 2025-12-17 | — | — | EP | disclosed |
| WO-2025236011-A1 | COMPOSITIONS FOR PHOSPHOROUS-AZOLE EXCHANGE CHEMISTRY AND USE THEREOF TO TARGET FUNCTIONAL PROTEIN SITES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-4577524-A1 | METHODS OF MANUFACTURING KINASE INHIBITORS | Insilico Medicine IP Limited (HK) | 2025-07-02 | — | — | EP | disclosed |
| WO-2025132825-A1 | 1H-IMIDAZO[4,5-C]QUINOLINE METAL-BASED COMPLEXES USEFUL AS MEDICAMENTS | FUNDACIÓN DONOSTIA INTERNATIONAL PHYSICS CENTER - DIPC (ES) | 2025-06-26 | — | — | WO | disclosed |
| US-20250197583-A1 | THERMALLY TREATED POLYAMIC AMIDE AEROGEL | Blueshift Materials, Inc. (US) | 2025-06-19 | — | — | US | disclosed |
| US-20250179059-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-06-05 | — | — | US | disclosed |
| CN-119923387-A | Method for producing kinase inhibitors | 英矽智能科技知识产权有限公司 | 2025-05-02 | — | — | CN | disclosed |
| US-20250109270-A1 | THERMALLY TREATED POLYAMIC AMIDE AEROGEL | Blueshift Materials, Inc. | 2025-04-03 | — | — | US | disclosed |
| US-6100404-A | Erythromycin compounds | HOECHST MARION ROUSSEL (FR) | 2000-08-08 | — | — | US | disclosed |
| CN-1052984-C | Novel erythromycin derivatives, process for their preparation and their use as medicaments | ROUSSEL UCLAF (FR) | 2000-05-31 | — | — | CN | disclosed |
| CN-1229082-A | Amine compound and its acid addition salt | ROUSSEL UCLAF (FR) | 1999-09-22 | — | — | CN | disclosed |
| EP-0680967-B1 | Erythromycin derivatives, their process of preparation and their use as medicaments | HOECHST MARION ROUSSEL INC (FR) | 1998-10-14 | — | — | EP | disclosed |
| CN-1151746-A | Novel erythromycin derivatives, process for their preparation and their use as medicaments | ROUSSEL UCLAF (FR) | 1997-06-11 | — | — | CN | disclosed |
| US-5635485-A | Erythromycin compounds | ROUSSEL UCLAF (FR) | 1997-06-03 | — | — | US | disclosed |
| WO-1995029929-A1 | NOVEL ERYTHROMYCIN DERIVATIVES, METHOD FOR THEIR PREPARATION AND THEIR USE AS DRUGS | ROUSSEL UCLAF (FR) | 1995-11-09 | — | — | WO | disclosed |
| EP-0680967-A1 | Erythromycin derivatives, their process of preparation and their use as medicaments | ROUSSEL-UCLAF (FR) | 1995-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179059-A1 | ANTICANCER COMPOUNDS | BET1, BRD4, BICRA | MAPK1 2457/4885SMN1; SMN2 4326/4885POLB 594/4885 |
| US-20140031289-A1 | POLY(ORGANOPHOSPHAZENE) CONTAINING DEGRADATION CONTROLLABLE IONIC GROUP, PREPARATION METHOD THEREOF AND USE THEREOF | PHOSPHO1, PLCB3, INPP5D | MAPK1 1786/4885SMN1; SMN2 2329/4885POLB 889/4885 |
| US-20110136796-A1 | IDO Inhibitors | IDO1, IDO2, INMT | MAPK1 2450/4885SMN1; SMN2 4704/4885POLB 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.